Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout

By Bryan Koenig · December 5, 2023, 5:06 PM EST

Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing...

To view the full article, register now.

Documents

Case Information

Case Title

IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION

Case Number

2:19-cv-07532

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 01, 2019